Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Dementia – risk factors, research and treatment

There are over ten million new cases of dementia each year worldwide, which translates into one new case every 3.2 seconds

- PMLiVE

Surrogate endpoints in HTA: Reflections on my HTAi panel discussion

Calum Jones (Associate Director – Health Economics, Mtech Access) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health...

Petauri Evidence

- PMLiVE

US and European Market Access for Medical Devices – Free Guide

We are delighted to announce that the second edition of our popular introductory guide: ‘Market access stakeholders and processes for medical devices in key European markets’ is now available. Our...

Petauri Evidence

Say Goodbye to Costly Delays – Origins’ Clinical Trial Participant Simulations Have the Answer!

Lack of Patient Involvement in Clinical Trial Designs Causes Major Issues Low recruitment and retention of clinical trials is a key issue faced by many clinical trials. These can lead...

Origins – The Patient Focused Specialists

- PMLiVE

FDA approves Samsung Bioepis’ Stelara biosimilar Pyzchiva for inflammatory conditions

The drug has been authorised to treat plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimen recommended by CHMP to treat endometrial cancer

Almost 125,000 cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

- PMLiVE

Almirall’s Ilumetri shown to improve and maintain well-being in plaque psoriasis patients

Nearly 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Find your brand’s edge, with dynamic competitive simulations

How the best teams in pharma stay at the top of their game

- PMLiVE

Johnson & Johnson’s Rybrevant granted EC approval for first-line NSCLC use

The drug was previously approved by the EU regulator for use after the failure of platinum-based therapy

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links